leisure time -WSS

leisure time

author：explore 2025-09-27 09:40:22 - browse：2

Ula Jurkunas, associate director of the cornea service at Mass Eye and Ear, performs the first CALEC surgery. Courtesy Mass Eye and Ear

The first time Phillip Durst saw the big A on the chart, he could hardly believe it. It was the first in a series of letters to check his vision in his left eye. “They keep flipping the chart and it keeps getting smaller and smaller, and I keep identifying the letters — that was huge,” said Durst. “It’s like a miracle.”

A year earlier, in April 2017, Durst had lost sight from that same eye after it was hit by a caustic water treatment solution in a work accident. The damage was so severe that a standard corneal transplant would not resolve it. But in April 2018, he underwent a new, innovative procedure: An eye stem cell transplant led by Ula Jurkunas, the associate director of the cornea service at Mass Eye and Ear in Boston.

Durst, now 51 years old, is the first of four patients who were included in a Phase 1 trial of Cultivated Autologous Limbal Epithelial Cell (CALEC) transplant, the results of which were published Friday in Science Advances. The procedure allowed him to become a suitable candidate for another surgery, the artificial corneal transplant, while rehabilitating his vision — and his life.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Democrats decry new health bill for going easy on private equity

focus

entertainment

focus

WSS

Readout LOUD podcast: How biotech is using artificial intelligence

New lawsuit accuses health insurer Cigna of denying claims in bulk

Truvian presents data for its desktop blood

Rise in cancer among younger people worries and puzzles doctors

Doctors' information doesn't help them choose wisely when sick

Truvian presents data for its desktop blood

knowledge

leisure time

entertainment

How one medical school became remarkably diverse

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Jerome Adams on the need for new antivirals for Covid

Medicare Advantage proposed rates disappoint insurers

Jerome Adams on the need for new antivirals for Covid

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

The cancer drug shortage isn’t new — and neither are the solutions

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Continuity nursing helped my family in our darkest PICU moments

PhRMA lawsuit over Medicare drug price negotiation tossed

hotspot

KalVista pill reduced swelling 'attacks' caused by genetic disease

Gilead might be held responsible for not developing a drug

CDC Director Mandy Cohen on transparency, trust, and health

Search called off for baby washed away in Pennsylvania flash flood

Medicare Advantage proposed rates disappoint insurers

KalVista pill reduced swelling 'attacks' caused by genetic disease

focus

entertainment

focus

entertainment